NCT01077518
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Nowotwór
chłoniak B-komórkowy
Chorzy
oporny na rituksymab
Faza badania
III
Sponsor badania
GSK
Termin
-
Linki
Dane kontaktowe
Gdynia; Warszawa; Wrocław